SEARCH

SEARCH BY CITATION

References

  • 1
    He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64–0802. Clin Pharmacokinet 1999; 37: 471484.
  • 2
    Oo C, Barrett J, Hill G, et al. Clinical pharmacokinetics and dose recommendation of oseltamivir suspension for the treatment of influenza in children. Paediatr Drugs 2001; 3: 229236.
  • 3
    Maton PN, Burton ME. Antacids revisited. a review of their clinical pharmacology and recommended therapeutic use. Drugs 1999; 57: 855870.
  • 4
    Welling PG. Interactions affecting drug absorption. Clin Pharmacokinet 1984; 9: 404434.
  • 5
    Hurwitz A. Antacid therapy and drug kinetics. Clin Pharmacokinet 1977; 2: 269280.
  • 6
    Reynolds JC. The clinical importance of drug interactions with anti-ulcer therapy. J Clin Gastroenterol 1990; 12(Suppl 2): S54S63.
  • 7
    Gugler AH. Effects of antacids on the clinical pharmacokinetics of drugs: an update. Clin Pharmacokinet 1990; 18: 210219.
  • 8
    Lomaestro BM, Bailie GR. Absorption interactions with flouroquinolones. Drug Safety 1995; 12: 314333.
  • 9
    Wiltshire H, Wiltshire B, Citron A, et al. Development of a high-performance liquid chromatographic mass spectrometric assay for the specific and sensitive quantification of Ro 64–0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine. J Chromatogr B 2000; 745: 373388.
  • 10
    D’Arcy PF, McElnay JC. Drug–antacid interactions: assessment of clinical importance. Drug Intell Clin Pharm 1987; 21: 607617.